Cyclacel Pharmaceuticals, Inc.
CYCC
$0.3181
-$0.0359-10.14%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 43.00K | 74.00K | 80.00K | 449.00K | 420.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 43.00K | 74.00K | 80.00K | 449.00K | 420.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 43.00K | 74.00K | 80.00K | 449.00K | 420.00K |
| SG&A Expenses | 5.41M | 6.34M | 6.72M | 6.67M | 6.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.05M | 15.61M | 20.28M | 22.94M | 25.87M |
| Operating Income | -12.00M | -15.54M | -20.20M | -22.49M | -25.45M |
| Income Before Tax | -11.99M | -15.83M | -20.36M | -22.73M | -25.55M |
| Income Tax Expenses | -782.00K | -2.40M | -2.86M | -3.03M | -3.00M |
| Earnings from Continuing Operations | -11.21 | -13.43 | -17.51 | -19.70 | -22.56 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.21M | -13.43M | -17.51M | -19.70M | -22.56M |
| EBIT | -12.00M | -15.54M | -20.20M | -22.49M | -25.45M |
| EBITDA | -12.00M | -15.52M | -20.19M | -22.46M | -25.42M |
| EPS Basic | -5.31 | -11.21 | -17.52 | -22.29 | -27.02 |
| Normalized Basic EPS | -4.10 | -8.14 | -12.48 | -15.71 | -18.97 |
| EPS Diluted | -5.31 | -11.21 | -17.52 | -22.29 | -27.02 |
| Normalized Diluted EPS | -4.10 | -8.14 | -12.48 | -15.71 | -18.97 |
| Average Basic Shares Outstanding | 14.50M | 6.11M | 4.80M | 3.83M | 3.37M |
| Average Diluted Shares Outstanding | 14.50M | 6.11M | 4.80M | 3.83M | 3.37M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -0.37% | -0.57% | -0.77% | -0.89% |